Personalizing an Ovulation Medication Based on Your Genes
Pharmacogenomics of an ovulation modulator and the impact on delay of ovulation
This project looks at how a common medication used to delay ovulation might work differently for people based on their genes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11132813 on NIH RePORTER |
What this research studies
This project explores how a medication called ulipristal acetate (UPA), used to delay ovulation, is processed by the body. We know that a specific enzyme, CYP3A5, breaks down UPA, and some people have a more active version of this enzyme due to their genes. We believe that UPA might be less effective in preventing ovulation for those with the active CYP3A5 gene variant. We will conduct studies in a non-human model to see how UPA levels are affected within the ovary and then perform clinical studies with human participants to see if their CYP3A5 gene type influences how well UPA works.
Who could benefit from this research
Good fit: Patients who use ulipristal acetate (UPA) for ovulation modulation and are interested in understanding how their genetics might affect its effectiveness could be ideal candidates.
Not a fit: Patients not using ulipristal acetate or those whose ovulation is not being modulated would likely not receive direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could help doctors personalize ovulation medication dosages, making it more effective for individuals based on their genetic makeup.
How similar studies have performed: While the general concept of pharmacogenomics is established, this specific link between CYP3A5 genotype and UPA efficacy in ovulation modulation is being explored in this project.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Edelman, Alison B — Oregon Health & Science University
- Study coordinator: Edelman, Alison B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.